Lapatinib also exhibited antitumor activity in these ErbB2-overexpressing tumor models, but AST1306 was more efficacious than lapatinib in the SK-OV-3 xenograft tumor model when given at the same dose and schedule. The gene discussed is ERBB2; the disease is neoplasm.